SCHEMBL4049433

SCHEMBL4049433

O=C(Nc1cccc(Cl)c1Cl)Nc1cc(-c2ccccc2)nn1-c1cccc(CO)c1

nearest known ligand 0.81

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 13/20 0.81
RAF1 P04049 1/20 0.58
BRAF P15056 1/20 0.58
EPHB2 P29323 1/20 0.58
GRM5 P41594 3/20 0.53
PTPN1 P18031 1/20 0.53
ABL1 P00519 1/20 0.52
ABL2 P42684 1/20 0.52
MAPK8 P45983 1/20 0.52
MAPK11 Q15759 1/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
MAPT P10636 1/20 0.51
NTRK1 P04629 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2082042 0.91 MAPK14 (0.86) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL2081541 0.90 MAPK14 (1.00) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL2082364 0.88 MAPK14 (0.77) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL2081766 0.87 MAPK14 (0.82) MAPK14RAF1BRAFEPHB2ABL1
SCHEMBL4052308 0.85 MAPK14 (0.82) MAPK14RAF1BRAFEPHB2ABL1
SCHEMBL2080577 0.85 MAPK14 (0.73) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL13576980 0.85 MAPK14 (0.72) MAPK14GRM5PTPN1ABL1ABL2
SCHEMBL2082683 0.84 MAPK14 (0.75) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL2081435 0.84 MAPK14 (0.74) MAPK14RAF1BRAFEPHB2GRM5
SCHEMBL4298803 0.83 PTPN1 (0.64) MAPK14GRM5PTPN1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US claimed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 EP claimed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 EP claimed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 WO claimed
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC 2009-12-17 US disclosed
EP-1836173-A4 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS LLC (US) 2009-07-08 EP disclosed
US-20080220497-A1 Modulation of protein functionalities DECIPHERA PHARMACEUTICALS LLC 2008-09-11 US disclosed
US-20080220497-A1 Modulation of protein functionalities DECIPHERA PHARMACEUTICALS LLC 2008-09-11 US disclosed
EP-1836173-A2 ANTI-INFLAMMATORY MEDICAMENTS Deciphera Pharmaceuticals, LLC (US) 2007-09-26 EP disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
US-20070191336-A1 p38 kinase inhibitors DECIPHERA PHARMACEUTICALS, LLC 2007-08-16 US disclosed
WO-2007008917-A2 MODULATION OF PROTEIN FUNCTIONALITIES DECIPHERA PHARMACEUTICALS, LLC (US) 2007-01-18 WO disclosed
WO-2006081034-A2 ANTI-INFLAMMATORY MEDICAMENTS DECIPHERA PHARMACEUTICALS, LLC (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312349-A1 ANTI-INFLAMMATORY MEDICAMENTS ABL2, ABL1, PTK2 MAPK14 80/4885RAF1 189/4885BRAF 23/4885
US-20070191336-A1 p38 kinase inhibitors MAPK1, MAP3K8, MAP3K1 MAPK14 29/4885RAF1 160/4885BRAF 107/4885
US-20080220497-A1 Modulation of protein functionalities C1QBP, SERPINA6, CD2BP2 MAPK14 2241/4885RAF1 1944/4885BRAF 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.